Mutational analysis of class III receptor tyrosine kinases (C‐KIT, C‐FMS, FLT3) in idiopathic myelofibrosis

No abstract is available for this paper.

• Publication year

  2003

• Venue

  British Journal of Haematology

• Publication date

  2003-02-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1046/j.1365-2141.2003.04108.xPMID 12580961
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• FLT3 internal tandem duplication mutations are rare in agnogenic myeloid metaplasia.

  2002cited by this paper
• Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies

  2002cited by this paper
• Class III receptor tyrosine kinases: role in leukaemogenesis

  2002cited by this paper
• Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies.

  2001cited by this paper
• Identification of novel FLT‐3 Asp835 mutations in adult acute myeloid leukaemia

  2001cited by this paper
• Reply to vom dahl et al

  2001cited by this paper
• FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high-risk group.

  2000cited by this paper
• FLT3 internal tandem duplication mutations in adult acute myeloid leukaemia define a high‐risk group

  2000cited by this paper
• C-kit mutations in core binding factor leukemias.

  2000cited by this paper
• Single-nucleotide polymorphisms can cause different structural folds of mRNA.

  1999cited by this paper
• Molecular evolution of acute myeloid leukaemia in relapse: unstable N‐ras and FLT3 genes compared with p53 gene

  1999cited by this paper
• A rapid method for haemophilia B mutation detection using conformation sensitive gel electrophoresis

  1999cited by this paper
• High expression but no internal tandem duplication of FLT3 in normal hematopoietic cells.

  1999cited by this paper
• Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia.

  1999influential reference
• c‐kit proto‐oncogene exon 8 in‐frame deletion plus insertion mutations in acute myeloid leukaemia

  1999cited by this paper
• Precise Carrier Diagnosis in Families with Haemophilia A: Use of Conformation Sensitive Gel Electrophoresis for Mutation Screening and Polymorphism Analysis

  1998cited by this paper
• Pathogenesis and management of idiopathic myelofibrosis.

  1998cited by this paper
• 3 Pathogenesis and management of idiopathic myelofibrosis

  1998cited by this paper
• c-kit Point mutation in patients with myeloproliferative disorders.

  1997cited by this paper
• Oncogenic activation of the alphaPDGFR defines a domain that negatively regulates receptor dimerization.

  1997cited by this paper
• Internal tandem duplication of the FLT3 gene is preferentially seen in acute myeloid leukemia and myelodysplastic syndrome among various hematological malignancies. A study on a large series of patients and cell lines

  1997cited by this paper
• Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia

  1997cited by this paper
• Genetic aberrations in the development and subsequent progression of myelodysplastic syndrome.

  1997cited by this paper
• Sequence analysis of two genomic regions containing the KIT and the FMS receptor tyrosine kinase genes.

  1997cited by this paper
• A novel potentially diagnostic polymorphism (4894 A/C) in exon 10 of the human c-kit proto-oncogene.

  1996cited by this paper
• Analysis of c-kit gene integrity in aplastic anemia.

  1996cited by this paper
• Implication of CD44 in adhesion‐mediated overproduction of TGF‐β and IL‐1 in monocytes from patients with bone marrow fibrosis

  1996cited by this paper
• Internal tandem duplication of the flt3 gene found in acute myeloid leukemia.

  1996cited by this paper
• Spontaneous granulocyte-macrophage colony growth by peripheral blood mononuclear cells in myeloproliferative disorders.

  1996cited by this paper
• c‐kit point mutation of extracellular domain in patients with myeloproliferative disorders

  1995cited by this paper
• Karyotypic and ras gene mutational analysis in idiopathic myelofibrosis

  1994cited by this paper
• Expression of the c-kit proto-oncogene in myeloproliferative disorders and myelodysplastic syndromes.

  1994cited by this paper
• Monocyte adhesion in patients with bone marrow fibrosis is required for the production of fibrogenic cytokines. Potential role for interleukin-1 and TGF-beta.

  1994cited by this paper
• Ki-S1 and proliferating cell nuclear antigen expression of bone marrow macrophages. Immunohistochemical and morphometric study including reactive (inflammatory) myelitis, secondary aplastic anemia, AIDS, myelodysplastic syndromes and primary (idiopathic) osteomyelofibrosis.

  1994cited by this paper
• Human FLT3/FLK2 gene: cDNA cloning and expression in hematopoietic cells.

  1993cited by this paper
• Two new polymorphisms but no mutations of the KIT gene in patients with myelodysplasia at positions corresponding to human FMS and murine W locus mutational hot spots.

  1993cited by this paper
• c-fms point mutations in acute myeloid leukemia: fact or fiction?

  1993cited by this paper
• Random mutagenesis of CSF‐1 receptor (FMS) reveals multiple sites for activating mutations within the extracellular domain.

  1992cited by this paper
• Dominant negative and loss of function mutations of the c-kit (mast/stem cell growth factor receptor) proto-oncogene in human piebaldism.

  1992cited by this paper
• Molecular Definition of Interstitial Deletions of Chromosome 13 in Leukemic Cells

  1991cited by this paper
• PROPOSED CLASSIFICATION FOR THE MYELODYSPLASIA/MYELOFIBROSIS SYNDROMES

  1991cited by this paper
• FMS mutations in myelodysplastic, leukemic, and normal subjects.

  1990cited by this paper
• Mutation of the human FMS gene (M-CSF receptor) in myelodysplastic syndromes and acute myeloid leukemia.

  1990cited by this paper
• Signal transduction by receptors with tyrosine kinase activity.

  1990cited by this paper
• Myelofibrosis in primary myelodysplastic syndromes: a clinico‐morphological study of 10 cases

  1989cited by this paper
• Nucleotide sequence and structural organization of the human FMS proto-oncogene.

  1989cited by this paper
• Characteristics of circulating megakaryocyte progenitors (CFU‐MK) in patients with primary myelofibrosis

  1988cited by this paper
• Growth factor receptor tyrosine kinases.

  1988cited by this paper
• Truncation of the human EGF receptor leads to differential transforming potentials in primary avian fibroblasts and erythroblasts.

  1988cited by this paper
• Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand.

  1987cited by this paper
• Effects of recombinant alpha and gamma interferons on the in vitro growth of circulating hematopoietic progenitor cells (CFU-GEMM, CFU-Mk, BFU-E, and CFU-GM) from patients with myelofibrosis with myeloid metaplasia.

  1987cited by this paper
• Frequent c-fms activation by proviral insertion in mouse myeloblastic leukaemias

  1987cited by this paper
• Structural alteration of viral homologue of receptor proto-oncogene fms at carboxyl terminus

  1986cited by this paper
• Idiopathic myeloid metaplasia. Its evolution into acute leukemia.

  1973cited by this paper

• Design and Synthesis of Pyridine-Based Pyrrolo[2,3-d]pyrimidine Analogs as CSF1R Inhibitors: Molecular Hybridization and Scaffold Hopping Approach

  2025cites this paper
• Cross-family Signaling: PDGF Mediates VEGFR Activation and Endothelial Function

  2025cites this paper
• Discovery of N-(5-amido-2-methylphenyl)-5-methylisoxazole-3-carboxamide as dual CSF-1R/c-Kit Inhibitors with improved stability and BBB permeability.

  2024cites this paper
• Targeting the CSF-1/CSF-1R Axis: Exploring the Potential of CSF1R Inhibitors in Neurodegenerative Diseases.

  2024cites this paper
• Bayesian Optimization in the Latent Space of a Variational Autoencoder for the Generation of Selective FLT3 Inhibitors

  2023cites this paper
• Identification and in silico analysis of noval alteration Arg420Gly in KIT proto oncogene among acute myeloid leukemia patients

  2022cites this paper
• Proteolysis-Targeting Chimera (PROTAC) Modification of Dovitinib Enhances the Antiproliferative Effect against FLT3-ITD-Positive Acute Myeloid Leukemia Cells.

  2021cites this paper
• Discovery of potent colony-stimulating factor 1 receptor inhibitors by replacement of hinge-binder moieties.

  2021cites this paper
• Current and emerging molecular and epigenetic disease entities in acute myeloid leukemia and a critical assessment of their therapeutic modalities.

  2020cites this paper
• Discovery of N-(4-(6-Acetamidopyrimidin-4-yloxy)phenyl)-2-(2-(trifluoromethyl)phenyl)acetamide (CHMFL-FLT3-335) as a Potent FMS-like Tyrosine Kinase 3 Internal Tandem Duplication (FLT3-ITD) Mutant Selective Inhibitor for Acute Myeloid Leukemia.

  2018cites this paper
• Resveratrol improved detrusor fibrosis induced by mast cells during progression of chronic prostatitis in rats

  2017cites this paper
• Resveratrol improves urinary dysfunction in rats with chronic prostatitis and suppresses the activity of the stem cell factor/c-Kit signaling pathway.

  2017cites this paper
• Resveratrol improves prostate fibrosis during progression of urinary dysfunction in chronic prostatitis.

  2017cites this paper
• A Phase II trial of tandutinib (MLN 518) in combination with bevacizumab for patients with recurrent glioblastoma.

  2016cites this paper
• The role of pacritinib in the management of myelofibrosis

  2014cites this paper
• FLT3 Mutations in Myeloproliferative Neoplasms: The Beaumont Experience

  2013cites this paper
• Discovery of AC710, a Globally Selective Inhibitor of Platelet-Derived Growth Factor Receptor-Family Kinases.

  2012cites this paper
• Rôle du couple Flt3-ligand/Flt3 et de l'activation des "Mitogen-activated protein kinases" p38 dans la dysmégacaryopoïèse des patients atteints de myélofibrose primitive

  2011cites this paper
• Osteoclast Differentiation and Function

  2009cites this paper
• Screening patients with polycythemia vera for c-Kit mutations

  2009cites this paper
• Imatinib sensitivity as a consequence of a CSF1R-Y571D mutation and CSF1/CSF1R signaling abnormalities in the cell line GDM1

  2009cites this paper
• CSF1R copy number changes, point mutations, and RNA and protein overexpression in renal cell carcinomas

  2009cites this paper
• FLT3-mediated p38-MAPK activation participates in the control of megakaryopoiesis in primary myelofibrosis.

  2007cites this paper
• Chronic Idiopathic Myelofibrosis

  2007cites this paper
• Relevância biológica e clínica das alterações do número de cópias e da expressão do gene CSF1R nos carcinomas renais

  2007cites this paper
• Idiopathic myelofibrosis: pathogenesis to treatment

  2006cites this paper
• Platelet-derived growth factor receptor family mutations in gastrointestinal stromal tumours

  2006cites this paper
• FLT3/D835 mutation and inversion of chromosome 16 in leukemic transformation of myelofibrosis.

  2006cites this paper
• Pathogenesis of myelofibrosis with myeloid metaplasia.

  2005cites this paper
• Cytogenetic and molecular genetic abnormalities in agnogenic myeloid metaplasia.

  2005cites this paper
• Clinical Significance of FLT3 in Leukemia

  2005cites this paper
• The biology of Kit in disease and the application of pharmacogenetics.

  2004cites this paper
• Considerations for targeting malignant stem cells in leukemia.

  2004cites this paper
• Chronic myelogenous leukemia and myeloproliferative disease.

  2004cites this paper
• Imatinib mesylate (STI571) for myeloid malignancies other than CML.

  2004cites this paper
• FLT3: ITDoes matter in leukemia

  2003cites this paper